APP and Alzheimer disease: Figure 2 shows immunofluorescence against the Aβ1–42 antibody and ActinRedTM 555 labeling after 48-h incubation with non-AD extracts (Fig. 2a) and Aβ-enriched extracts from AD1 (Fig. 2b, c) and AD2 (Fig. 2d, e).